JPMorgan Chase & Co. Boosts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $54.00

Halozyme Therapeutics (NASDAQ:HALOGet Rating) had its price objective upped by JPMorgan Chase & Co. from $53.00 to $54.00 in a research note issued to investors on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research analysts also recently weighed in on the stock. JMP Securities upped their target price on shares of Halozyme Therapeutics from $60.00 to $62.00 and gave the company a market outperform rating in a research note on Wednesday, November 9th. Morgan Stanley initiated coverage on shares of Halozyme Therapeutics in a research report on Friday, September 9th. They issued an overweight rating and a $50.00 price objective for the company. SVB Leerink raised their target price on Halozyme Therapeutics from $52.00 to $62.00 and gave the company an outperform rating in a research note on Monday, November 14th. Finally, StockNews.com began coverage on Halozyme Therapeutics in a research note on Wednesday, October 12th. They issued a hold rating on the stock. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $54.50.

Halozyme Therapeutics Stock Up 0.6 %

NASDAQ HALO opened at $53.63 on Tuesday. The company has a quick ratio of 5.03, a current ratio of 5.97 and a debt-to-equity ratio of 15.37. Halozyme Therapeutics has a fifty-two week low of $31.36 and a fifty-two week high of $54.88. The business has a 50 day moving average price of $45.23 and a two-hundred day moving average price of $44.93. The stock has a market cap of $7.25 billion, a PE ratio of 35.99, a P/E/G ratio of 0.84 and a beta of 1.22.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $53.81, for a total value of $269,050.00. Following the sale, the chief financial officer now directly owns 4,045 shares in the company, valued at $217,661.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $52.15, for a total value of $521,500.00. Following the transaction, the chief executive officer now owns 587,177 shares of the company’s stock, valued at approximately $30,621,280.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $53.81, for a total value of $269,050.00. Following the completion of the transaction, the chief financial officer now owns 4,045 shares in the company, valued at $217,661.45. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,000 shares of company stock valued at $1,331,850. Company insiders own 2.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HALO. First Horizon Advisors Inc. boosted its position in Halozyme Therapeutics by 188.8% during the second quarter. First Horizon Advisors Inc. now owns 722 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 472 shares during the last quarter. Meeder Asset Management Inc. boosted its position in Halozyme Therapeutics by 223.6% during the second quarter. Meeder Asset Management Inc. now owns 741 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 512 shares during the period. Brown Brothers Harriman & Co. acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at $35,000. San Luis Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at about $36,000. Finally, IFP Advisors Inc increased its position in Halozyme Therapeutics by 87.9% in the 3rd quarter. IFP Advisors Inc now owns 1,717 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 803 shares during the period. 91.72% of the stock is owned by institutional investors and hedge funds.

About Halozyme Therapeutics

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Articles

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.